AKTX — Akari Therapeutics Share Price
Last trade - 00:00- $32.79m
- $29.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 4,193 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Directors
- Ray Prudo CHM (76)
- Clive Richardson CEO (56)
- Torsten Hombeck CFO (51)
- Michael Grissinger DRC (67)
- David Byrne IND (61)
- Peter Feldschreiber IND (77)
- James Hill IND (75)
- Stuart Ungar IND (77)
- Donald Williams IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 7th, 2004
- Public Since
- January 31st, 2014
- No. of Shareholders
- 350
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 24,289,232,698
- Address
- 22 BOSTON WHARF ROAD, FL 7, BOSTON, 02210
- Web
- https://www.akaritx.com/
- Phone
- +1 6463500702
- Auditors
- BDO USA, LLP
Upcoming Events for AKTX
Similar to AKTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
FAQ
As of Today at 19:09 UTC, shares in Akari Therapeutics are trading at $2.70. This share price information is delayed by 15 minutes.
Shares in Akari Therapeutics last closed at $2.70 and the price had moved by -23.08% over the past 365 days. In terms of relative price strength the Akari Therapeutics share price has underperformed the S&P500 Index by -42.75% over the past year.
The overall consensus recommendation for Akari Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAkari Therapeutics does not currently pay a dividend.
Akari Therapeutics does not currently pay a dividend.
Akari Therapeutics does not currently pay a dividend.
To buy shares in Akari Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.70, shares in Akari Therapeutics had a market capitalisation of $32.79m.
Here are the trading details for Akari Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AKTX
Based on an overall assessment of its quality, value and momentum Akari Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Akari Therapeutics is $80.00. That is 2862.96% above the last closing price of $2.70.
Analysts covering Akari Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.40 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akari Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +94.24%.
As of the last closing price of $2.70, shares in Akari Therapeutics were trading +3.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Akari Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Akari Therapeutics' management team is headed by:
- Ray Prudo - CHM
- Clive Richardson - CEO
- Torsten Hombeck - CFO
- Michael Grissinger - DRC
- David Byrne - IND
- Peter Feldschreiber - IND
- James Hill - IND
- Stuart Ungar - IND
- Donald Williams - IND